New drug combo shows promise for tough lung disease cases
NCT ID NCT02990286
First seen Jan 04, 2026 · Last updated Jun 16, 2026 · Updated 34 times
Summary
This study tested whether adding rituximab to standard mycophenolate mofetil (MMF) therapy helps people with interstitial lung disease (lung scarring) who didn't respond to initial treatment. 122 adults participated, and the main goal was to see if lung function improved after 6 months. The approach aims to better control the disease, not cure it.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LUNG DISEASE, INTERSTITIAL are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
AP-HM Hôpital NORD
Marseille, 13015, France
-
CHRU Tours
Tours, 37044, France
-
Chu Besancon
Besançon, 25030, France
-
Chu Dijon
Dijon, 21079, France
-
Chu Rennes
Rennes, 35033, France
Conditions
Explore the condition pages connected to this study.